Physician profile
Eric Moffet
NPI 1609984178
$21,206.36
in general payments reported to CMS, 2019-2025
28 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,162 · 2020: $2,691 · 2021: $3,077 · 2022: $2,622 · 2023: $3,410 · 2024: $2,839 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,321 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,321.49 |
| Education | $332.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,795.41 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $2,559.42 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $2,127.51 | 2019-2022 | |
| Abbvie INC. | $1,548.90 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,520.03 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,476.66 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $1,430.29 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $1,236.93 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $1,198.11 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $1,060.05 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $983.79 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $867.05 | 2019-2023 | Aplenzin |
| Allergan, INC. | $569.10 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $478.53 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $360.00 | 2019-2025 | Spravato |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $225.55 | 2020-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $166.94 | 2019-2022 | |
| Eisai INC. | $138.33 | 2020-2022 | |
| Stryker Corporation | $137.98 | 2025 | Citrefix, Anchorage, Pangea |
| E.R. Squibb & Sons, L.L.C. | $74.42 | 2025 | Cobenfy |
| Almatica Pharma LLC | $60.15 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $51.84 | 2019 | |
| Acadia Pharmaceuticals INC | $35.53 | 2020-2022 | |
| Lilly USA, LLC | $28.45 | 2025 | |
| Supernus Pharmaceuticals, INC. | $27.17 | 2023 | Qelbree |
| Tonix Medicines, INC. | $20.19 | 2025 | Tonmya |
| Neuronetics, INC. | $15.37 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Moffet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.